found that increased toxicity of that dose forced decreasing dose to approximately 600 mg, daily when considering the actually administered dose intensity. 43 – 45 Additionally, the French SPIRIT trial reported superior major molecular response (MMR
Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar
Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla and Arun S. Singh
age on outcome is controversial; limited data have indicated that the outcome for adults is not as promising as for adolescents, 14 , 15 but other studies have shown that adults are not always treated with the same chemotherapy dose intensity as
Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler
intensity in this arm. At 12 months, MMR was observed in 62% patients with an average dose intensity of 600 to 799 mg/d, and in 38% of patients with an average dose intensity of 400 to 599 mg/d. 16 These data suggest that patients who can tolerate high
Joseph M. Pepek, Christopher G. Willett and Brian G. Czito
radiation dose by partitioning a given radiation field into multiple smaller fields of different shapes and sizes, varying the radiation dose intensity between each area. 18 This is performed with either dynamic IMRT (where collimating leaves, or blocks
Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre and Gary H. Lyman
Moliterni A Zambetti M . 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study . BMJ 2005 ; 330 : 217 . 5. Lyman GH Dale DC Crawford J . Incidence and predictors of low dose-intensity in adjuvant
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III and Arti Hurria
between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older [abstract] . J Clin Oncol 2011 ; 29 ( Suppl ): Abstract 9000 . 17
Pooja Ghatalia and Elizabeth R. Plimack
Program. Cancer Stat Facts: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html . Accessed January 5, 2019 . 3. Sternberg CN , de Mulder PH , Schornagel JH , . Randomized phase III trial of high-dose-intensity
Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer and Maria Ho
dose-dense MVAC cohort compared with 13.2% in the standard MVAC cohort; one toxic death occurred in each arm, but less overall toxicity was seen in the dose-dense group. Based on these data, standard MVAC is inferior to high-dose-intensity MVAC in terms
Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus
. 40%, respectively; CCyR, 70% vs. 66%, respectively). In patients with high Sokal risk scores, MMR rates at 12 months were 51% for high-dose imatinib compared with 31% for standard-dose. The MMR rate also correlated with average dose intensity. At 12
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N. Winter and Joachim Yahalom
.They also showed that the use of growth factors with chemotherapy significantly increases the incidence of BPT (26% vs. 9%). Recently, 2 separate studies confirmed that ABVD chemotherapy can be safely administered at the full dose intensity without any
